Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Net margin is calculated as Net Income divided by its Revenue. Nanologica AB's Net Income for the
three
months ended in Mar. 2026 was kr65.19 Mil. Nanologica AB's Revenue for the
three
months ended in Mar. 2026 was kr21.46 Mil. Therefore, Nanologica AB's net margin for the quarter that ended in Mar. 2026 was 303.81%.
The historical rank and industry rank for Nanologica AB's Net Margin % or its related term are showing as below:
OSTO:NICA'
s Net Margin % Range Over the Past 10 Years
Min: -5208.39 Med: -477.7 Max: 78.97
Current: 78.97
OSTO:NICA's Net Margin % is ranked better than 97.02% of 941
companies
in the Biotechnology industry
Industry Median: -88.29
vs OSTO:NICA: 78.97
Nanologica AB (OSTO:NICA) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Nanologica AB Net Margin % Related Terms
Nanologica AB Net Margin % Historical Data
* Premium members only.
The historical data trend for Nanologica AB's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:NICA vs VRTX, REGN, ALNY: Net Margin % Comparison
For the Biotechnology subindustry, Nanologica AB's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nanologica AB Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nanologica AB's Net Margin % distribution charts can be found below:
* The bar in red indicates where Nanologica AB's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nanologica AB (OSTO:NICA) has a Net Margin % of 303.81% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Nanologica AB and its competitors. According to the industry distribution chart, Nanologica AB ranks #28 out of 941 companies in the Biotechnology industry, placing it in the top 3%.
Is Nanologica AB's Net Margin % too high?
Nanologica AB's current Net Margin % is 303.81%. Based on the distribution chart, Nanologica AB ranks #28 out of 941 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Nanologica AB has a GF Score™ of 45/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Nanologica AB's Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Nanologica AB ranks #28 out of 941 companies for Net Margin %. This places Nanologica AB in the top 3% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Nanologica AB and its competitors. Nanologica AB's current Net Margin % is 303.81%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nanologica AB stock overvalued right now?
Based on GuruFocus' analysis, Nanologica AB (OSTO:NICA) is currently considered Possible Value Trap. The stock's GF Value™ is kr4.24, compared to a current price of kr0.47 — trading 88.8% below its estimated fair value. The current Net Margin % is 303.81%. Nanologica AB's overall GF Score™ is 45/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Nanologica AB (OSTO:NICA), the current Net Margin % is 303.81% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nanologica AB (OSTO:NICA) Overvalued in 2026?
Based on GuruFocus' analysis, Nanologica AB stock appears to be undervalued.
The current stock price of kr0.47 is trading 88.8% below its estimated GF Value™ of kr4.24.
GuruFocus considers Nanologica AB to be Possible Value Trap.
Key valuation signals for OSTO:NICA:
Net Margin %: 303.81%
GF Value™: kr4.24 vs. price of kr0.47 (88.8% below fair value)
No single metric tells the full story. See the OSTO:NICA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nanologica AB is a Swedish life science tools company that develops, manufactures, and sells key consumables to pharmaceutical manufacturers. Its products are specially developed for the purification of peptide drugs, such as insulin and GLP-1 analogues. Due to effective purification and a long lifetime for the products, it can increase productivity and reduce costs for pharmaceutical manufacturers. The group operates in a world-wide niche market that is growing as a result of increased demand for drugs for the treatment of diabetes and obesity. The company's mission is to increase access to cost-effective drugs through its purification products and thereby contribute to more patients around the world having access to life-saving treatments.
45GF Score
Get the complete analysis for OSTO:NICA
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:NICA has been successfully added to your 
